ArticleCancer medicine2025
Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Perioperative cognitive dysfunction in bladder cancer patients, causal factors, and possible interventions.Frontiers in medicine · 2026Review
- Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer (BC) is one of the most common cancers and many patients will experience long-term survival. Non-urothelial second primary cancers (SPC) relatively frequently occur in the population of BC survivors.
methodsCzech National Cancer Registry was the principal data source for this study. The risk of development of non-urothelial SPC after BC was assessed by the standardized incidence ratio (SIR). The standardized mortality ratio (SMR) was utilized to determine the risk of death from SPC following BC.
resultsOf the total of 61,314 patients with BC, a cohort of 12,645 survivors diagnosed with a SPC were analyzed. Compared to the general population, the SIR of neoplasia was significantly increased in BC survivors, with a SIR of 1.75 (95% confidence interval [CI] 1.72-1.78) for all cancers, especially during the first 5 years after BC diagnosis. The SMR was increased in BC survivors (1.25; 95% CI 1.21-1.29) for all cancers. Lung cancer frequently occurred as a SPC and was associated with high mortality in BC survivors. BC survivors also had a higher risk of laryngeal cancer and other cancers known to be strongly associated with smoking, but also of soft tissue tumors, colorectal cancer, chronic lymphocytic leukemia, and thyroid cancer.
conclusionsThe present large registry-based study shows that BC survivors have a significantly higher risk of being diagnosed with another primary cancer compared to the general population, especially during the first 5 years after BC diagnosis. In addition to smoking-related cancers, increased incidence of some cancers not known to be associated with smoking was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.